| Identification | Back Directory | [Name]
Cyclopropanecarboxamide, N-[6-[6-[[3,5-difluoro-2-[(tetrahydro-2H-pyran-4-yl)oxy]phenyl]methyl]-5,6,7,8-tetrahydro-5-oxo-1,6-naphthyridin-3-yl]imidazo[1,2-b]pyridazin-2-yl]- | [CAS]
2682889-51-4 | [Synonyms]
RIPK1-IN-10
Cyclopropanecarboxamide, N-[6-[6-[[3,5-difluoro-2-[(tetrahydro-2H-pyran-4-yl)oxy]phenyl]methyl]-5,6,7,8-tetrahydro-5-oxo-1,6-naphthyridin-3-yl]imidazo[1,2-b]pyridazin-2-yl]- | [Molecular Formula]
C30H28F2N6O4 | [MOL File]
2682889-51-4.mol | [Molecular Weight]
574.58 |
| Chemical Properties | Back Directory | [density ]
1.55±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 31.25 mg/mL (54.39 mM; ultrasonic and warming and heat to 70°C) | [form ]
Solid | [pka]
9.36±0.20(Predicted) | [color ]
White to light yellow |
| Hazard Information | Back Directory | [Uses]
RIPK1-IN-10 is a potent RIPK1 inhibitor, example 37, extracted from patent WO2021160109[1]. | [References]
[1] ?Zhou FuSheng, et al. Dihydronaphthyridinone compound, and preparation method therefor and medical use thereof. Patent WO2021160109. |
|
|